Literature DB >> 18040832

Meeting practical challenges of a trial involving a multitude of treatment regimens: an example of a multi-center randomized controlled clinical trial in neuroAIDS.

Susanne May1, Scott Letendre, Richard Haubrich, J Allen McCutchan, Robert Heaton, Edmund Capparelli, Ronald Ellis.   

Abstract

Many clinical trials compare one specific treatment to a control or standard treatment. In HIV therapeutics, such fixed-regimen designs may be problematic as individualized treatment regimens are standard practice. Designing and implementing a trial that allows individualized treatment options poses particular challenges. In this example of a clinical trial in NeuroAIDS, it is hypothesized that some antiretroviral drugs [i.e., those that penetrate the blood-brain barrier sufficiently to inhibit HIV in the central nervous system (CNS)] will improve HIV neurocognitive impairment, whereas non-penetrating antiretrovirals will not be as effective in improving neurocognitive function. To test this hypothesis, a uniquely designed strategy trial was developed that consists of three essential components: (1) a scoring system that ranks regimens for CNS penetration based on semiquantitative criteria, (2) committee-established individualized regimen options that allow randomization to opposite ends of the CNS penetration spectrum, and (3) timely implementation across multiple centers via web-based resources. For the proposed trial, the three components are combined with an adaptive randomization scheme to minimize potential confounding by several important factors. A small pilot study demonstrated the feasibility and acceptability to providers. In conclusion, an innovative design can provide solutions to challenging practical issues in trials with multiple treatment options.

Entities:  

Mesh:

Year:  2007        PMID: 18040832     DOI: 10.1007/s11481-006-9057-8

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  26 in total

1.  Changes to AIDS dementia complex in the era of highly active antiretroviral therapy.

Authors:  G J Dore; P K Correll; Y Li; J M Kaldor; D A Cooper; B J Brew
Journal:  AIDS       Date:  1999-07-09       Impact factor: 4.177

2.  A multimodal assessment of driving performance in HIV infection.

Authors:  T D Marcotte; T Wolfson; T J Rosenthal; R K Heaton; R Gonzalez; R J Ellis; I Grant
Journal:  Neurology       Date:  2004-10-26       Impact factor: 9.910

3.  Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group.

Authors:  R J Ellis; R Deutsch; R K Heaton; T D Marcotte; J A McCutchan; J A Nelson; I Abramson; L J Thal; J H Atkinson; M R Wallace; I Grant
Journal:  Arch Neurol       Date:  1997-04

4.  Low blood-brain barrier permeability to azidothymidine (AZT), 3TC, and thymidine in the rat.

Authors:  D Wu; J G Clement; W M Pardridge
Journal:  Brain Res       Date:  1998-04-27       Impact factor: 3.252

5.  Paradigm shifts in clinical trials enabled by information technology.

Authors:  R G Marks; M Conlon; S J Ruberg
Journal:  Stat Med       Date:  2001 Sep 15-30       Impact factor: 2.373

6.  The relationship between employment and neuropsychological impairment in HIV infection.

Authors:  W G van Gorp; J P Baerwald; S J Ferrando; M C McElhiney; J G Rabkin
Journal:  J Int Neuropsychol Soc       Date:  1999-09       Impact factor: 2.892

7.  Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection.

Authors:  D W Haas; J Stone; L A Clough; B Johnson; P Spearman; V L Harris; J Nicotera; R H Johnson; S Raffanti; L Zhong; P Bergqwist; S Chamberlin; V Hoagland; W D Ju
Journal:  Clin Pharmacol Ther       Date:  2000-10       Impact factor: 6.875

8.  Symptoms and signs in dementia: synergy and antagonism.

Authors:  J E Graham; A B Mitnitski; A J Mogilner; D Gauvreau; K Rockwood
Journal:  Dementia       Date:  1996 Nov-Dec

9.  Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. HNRC Group. HIV Neurobehavioral Research Center.

Authors:  R K Heaton; R A Velin; J A McCutchan; S J Gulevich; J H Atkinson; M R Wallace; H P Godfrey; D A Kirson; I Grant
Journal:  Psychosom Med       Date:  1994 Jan-Feb       Impact factor: 4.312

10.  Neuropsychologic impairment in early HIV infection. A risk factor for work disability.

Authors:  S M Albert; K Marder; G Dooneief; K Bell; M Sano; G Todak; Y Stern
Journal:  Arch Neurol       Date:  1995-05
View more
  9 in total

1.  In vitro and Ex vivo Neurotoxic Effects of Efavirenz are Greater than Those of Other Common Antiretrovirals.

Authors:  Vincent T Ciavatta; Edyta K Bichler; Iris A Speigel; Courtney C Elder; Shavonne L Teng; William R Tyor; Paul S García
Journal:  Neurochem Res       Date:  2017-08-02       Impact factor: 3.996

2.  Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder.

Authors:  Ronald J Ellis; Scott Letendre; Florin Vaida; Richard Haubrich; Robert K Heaton; Ned Sacktor; David B Clifford; Brookie M Best; Susanne May; Anya Umlauf; Mariana Cherner; Chelsea Sanders; Craig Ballard; David M Simpson; Cheryl Jay; J Allen McCutchan
Journal:  Clin Infect Dis       Date:  2013-12-18       Impact factor: 9.079

Review 3.  CSF penetration by antiretroviral drugs.

Authors:  Christine Eisfeld; Doris Reichelt; Stefan Evers; Ingo Husstedt
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

4.  Imaging upregulated brain arachidonic acid metabolism in HIV-1 transgenic rats.

Authors:  Mireille Basselin; Epolia Ramadan; Miki Igarashi; Lisa Chang; Mei Chen; Andrew D Kraft; G Jean Harry; Stanley I Rapoport
Journal:  J Cereb Blood Flow Metab       Date:  2010-07-28       Impact factor: 6.200

Review 5.  Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review.

Authors:  Lucette A Cysique; Bruce J Brew
Journal:  Neuropsychol Rev       Date:  2009-05-09       Impact factor: 7.444

6.  Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

Authors:  Luis B Tovar-y-Romo; Namandjé N Bumpus; Daniel Pomerantz; Lindsay B Avery; Ned Sacktor; Justin C McArthur; Norman J Haughey
Journal:  J Pharmacol Exp Ther       Date:  2012-09-13       Impact factor: 4.030

7.  HIV and antiretroviral therapy: impact on the central nervous system.

Authors:  Ronald Ellis
Journal:  Prog Neurobiol       Date:  2009-10-24       Impact factor: 11.685

Review 8.  Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration?

Authors:  P P Koopmans; R Ellis; B M Best; S Letendre
Journal:  Neth J Med       Date:  2009-06       Impact factor: 1.422

Review 9.  Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research.

Authors:  Lucette A Cysique; Edward K Waters; Bruce J Brew
Journal:  BMC Neurol       Date:  2011-11-22       Impact factor: 2.474

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.